Stres üriner inkontinans hastalarında duloksetin tedavisi sonrası cinsel fonksiyon ve koital inkontinans durumu

OBJECTIVES: The aim of this study is to evaluate the effect of duloxetine treatment, used in the treatment of Stress Urinary Incontinence (SUI), on female sexual functions and coital incontinence (CI). MATERIAL and METHODS: Patients who applied to the urology outpatient clinic with complaints of SUI between January 2018 and July 2021 and used Duloxetine 2*40 mg (Nexetin, Nobel İlaç, Turkey) for 12 weeks were included in the study. Demographic characteristics of the patients were recorded. Medical and sexual histories of the patients were taken. In order to evaluate the sexual functions of the patients, the Female Sexual Function Index (FSFI) consisting of 19 questions was filled. It was asked whether there was CI or CI during penetration. RESULTS: A total of 64 patients were included in the study. The mean age of the patients was 43.64±11.08(35-58), and the mean BMI was 27.86±6.43(21.55-34.67) kg/m2. A significant improvement was observed in the patients’ total FSFI score, desire, arousal, lubrication and orgasm subscales after treatment (p<0.001 for each). While 49 patients described CI during sexual intercourse before treatment, CI persisted in 26 patients after 12 weeks of treatment. There was a significant improvement in CI rates after treatment (p<0.001). CONCLUSION: Duloxetine, which is used for the treatment of SUI, improves female sexual functions and reduces coital incontinence. Keywords: Stress urinary incontinence, duloxetine, female sexual function, coital incontinence